Drug intelligence / Profile preview

MQI-211

Development stage: Preclinical
Lead developer: Mabqi
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MQI-211 is a preclinical-stage, pH-sensitive antibody-drug conjugate (ADC) being developed by Mabqi for the treatment of oncology indications. Designed using Mabqi's proprietary LiteMab Sense platform, the candidate features a conditionally active antibody that preferentially binds its target in the acidic tumor microenvironment (TME) while showing reduced binding at physiological pH. This pH-sensitive targeting is intended to enhance the therapeutic index by maximizing tumor-specific drug delivery and minimizing on-target, off-tumor toxicities in healthy tissues. The specific biological target and payload of MQI-211 remain undisclosed.

Beyond the preview

Go deeper on MQI-211.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MQI-211.

Explore the full profile